ACM
RUBY

AlphaCrest Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

AlphaCrest Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,825
Closed -$462K – 1472
2021
Q3 		$462K Buy
+25,825
New +$562K 0.02% 953

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCrest Capital Management's RUBY Position: Q4 2021 in Review

AlphaCrest Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2021, closing a stake of 25,825 shares — an estimated $462K sold.

AlphaCrest Capital Management first reported a position in RUBY in Q3 2021 and held it in 1 quarter. The position peaked at $462K in Q3 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q4 2021.

  • AlphaCrest Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 25,825 Rubius Therapeutics, Inc shares in Q4 2021, an estimated $462K.
  • AlphaCrest Capital Management first reported a position in Rubius Therapeutics, Inc in Q3 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Rubius Therapeutics, Inc position peaked at $462K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2021.

Based on AlphaCrest Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.